Biocytics

BioCytics is excited to announce a new research collaboration with Eremid Genomic Services to advance our understanding of immune cells being studied for autologous cancer cell therapy. 🧬

Through single cell transcriptomics and TCR sequencing, this research will provide deeper molecular insight into immune cell characteristics, expansion, and reinvigoration. This type of characterization is an important part of advancing translational research and understanding the biology behind personalized cell based approaches.

We look forward to learning from the data and continuing to build partnerships that move innovative cancer research forward.

Read more about this collaboration at https://prn.to/3STRWWh

It’s National Postdoc Appreciation Week!🔬

Behind every breakthrough in cancer research are dedicated scientists asking important questions, exploring new approaches, and helping move discoveries from the laboratory toward the clinic. This week, we’re proud to celebrate two of our own postdoctoral scientists at the Human Applications Laboratory.

• Gaby Lizana-Vasquez, PhD, HAL Research Scientist III, whose work contributes to our cellular therapy research, with a focus on translating our bench research toward future human testing of our first autologous immune cell therapy, BCyIF1.

• Garrett Driscoll, PhD, HAL Research Scientist I, whose work supports our research through circulating tumor cell isolation and organoid models, helping us better understand cancer biology and explore new approaches to translational research.

Their expertise, curiosity, and dedication to scientific discovery play an important role in the work happening at BioCytics every day. We’re grateful for everything they bring to our team and to our mission of advancing innovative approaches in cancer research and cellular therapy.

Happy National Postdoc Appreciation Week!

BioCytics is excited to be part of the Charlotte Biomedical Sciences Symposium 2026 on September 14! 🧬

We’re proud to have three members of our team presenting and sharing their expertise:
🧬 Dr. John Powderly II MD | Expert Panel: Beyond the Bench - Charlotte Biotech
🔬 Dr. Renaud Warin | Upscaling Autologous Cancer Cell Therapies Manufactured at the Point of Care
🧪 Ari Polanco | Light-Assisted Drying for the Dry-State Preservation of Fetal Bovine Serum

Our team will also be at the BioCytics booth throughout the symposium. Stop by to meet the team and learn more about what we’re working on. We look forward to connecting with the Charlotte biomedical community!

📍 The Dubois Center at UNC Charlotte Center City
📅 September 14, 2026

BioCytics is growing! 🧬BioCytics is a biotechnology company located in Huntersville, NC focused on researching and developing novel cellular therapies and advancing innovative approaches to cancer treatment.

We currently have three opportunities available:
🔬 HAL Quality Manager
https://www.linkedin.com/jobs/view/4455947705/
🧪 Vice President, Quality & Regulatory
https://careerconnections.sitcancer.org/job/vice-president-of-quality-and-regulatory/85628298/
⚙️ Biomedical Equipment Technician
https://www.indeed.com/job/biomedical-equipment-technician-07bfa3362b989931

We’re looking for talented professionals who want to contribute to the development of innovative cellular therapies and support the research and infrastructure behind them.

Know someone who would be a great fit? Share this post or send it their way!

HAL Quality Manager at BioCytics Inc — Huntersville, NC | LinkedIn Jobs Apply for HAL Quality Manager at BioCytics Inc in Huntersville, NC. Full-time Mid-Senior level role. See responsibilities, qualifications, and similar jobs on LinkedIn.

Turning innovation into therapies starts with rethinking how we manufacture them. On July 23, the BioCytics team joined the G-Rex® Grant Tour in North Carolina for a day of conversations and exploration around the future of cell and gene therapy.

We were especially proud to see our Founder & CEO, Dr. John Powderly II, participate as a panelist during the Business Roundtable, sharing his perspective on biotechnology business models, the future of therapeutic development, and the growing role of Point-of-Care (POC) manufacturing.

Our scientific team also presented a poster highlighting how BioCytics is leveraging G-Rex® technology within our POC manufacturing platform to advance rare cell-based therapies for cancer.

Thank you to the organizers, fellow participants, and everyone who connected with our team throughout the day. We’re excited to keep building partnerships and advancing innovative approaches to cell-based cancer therapies.

BioCytics is proud to announce a strategic alliance with LIDE Biotech to advance screening platforms and companion diagnostics for immune based cancer cell therapies. 🧬

By combining BioCytics’ expertise in patient derived tumor and immune cells with LIDE’s advanced PDX, miniPDX®, and immuno oncology PDX models, this collaboration will help us investigate treatment response, resistance, tumor cell death, and the molecular pathways that shape therapeutic outcomes.

Our initial work will leverage patient derived biospecimens to develop models that can help bridge preclinical research and personalized cancer treatment.

We are excited to explore what this collaboration can uncover and to continue advancing approaches that bring promising immuno oncology research closer to the patients who need it.

👉 Read the full press release: https://prn.to/4ycWIwP

The future of cell and gene therapy manufacturing depends on the ideas, expertise, and collaboration that bring the industry together.

This past week, BioCytics Inc was proud to attend the 2026 CMaT Annual Summit, with Gaby Lizana-Vasquez, Ph.D. and Ritvik Satyanarayanan representing our team and connecting with researchers, industry leaders, partners, and innovators from across the field.

Gaby joined the Industry Panel: “The Future of Cell and Gene Therapy Manufacturing,” contributing to an important conversation around the evolving landscape of manufacturing and the opportunities ahead for cell and gene therapies. Beyond the panel, our team had the opportunity to connect with collaborators and colleagues, exchange ideas, and explore new opportunities to advance innovative approaches to cell and gene therapy manufacturing.

Thank you to the Cell Manufacturing Technologies (CMaT) team and everyone who took the time to connect with BioCytics. We’re grateful to be part of these conversations and look forward to continuing to build partnerships that help move the field forward.

We're excited to share that Gaby Lizana-Vasquez, PhD, HAL Research Scientist, and Ritvik Satyanarayanan, MS, HAL GMP Manufacturing Associate, will be representing BioCytics at the CMaT Annual Summit in Atlanta, Georgia, August 5–7.

The CMaT Annual Summit brings together leaders across the cell manufacturing ecosystem to discuss the latest advances in cell therapy manufacturing, innovation, and commercialization.

If you'll be attending, we'd love to connect! Whether you're interested in learning more about BioCytics' research capabilities, GMP manufacturing services, or exploring potential collaborations, Gaby and Ritvik are available to meet throughout the event.

🚀 We are thrilled to announce that Rajeev Shrimali, Ph.D., PMP has joined our team as the Vice President of Translational Research Services.

Dr. Shrimali is a translational drug development strategic leader with 20+ years of advancing oncology and immunology programs from concept to clinic through FDA approval across therapeutic modalities. His expertise spans tumor immunology, tumor microenvironment (TME), oncogenic signaling, immune cell interactions, mechanisms of resistance and immune escape, and the development of AI/ML driven biomarker based innovative immune-modulating and targeted therapies and their combinations. He is NCI, Surgery Branch–mentored by Dr. Steven Rosenberg in cellular immunotherapy. With a PMP (PMI) and AI/ML (MIT Sloan) certified; he brings proven cross-functional program and team leadership at global pharma, biotech's, CRO and academia. Dr. Shrimali has transformed program vision into publications, innovative pipelines, business growth and patient benefit.

"I am excited to collaboratively and diligently further strengthen our highly effective programs, platforms, products and cross functional teams while advancing the boundaries of immune cell therapies for our patients, partners and CBOI/BioCytics. I look forward to aligning my enthusiasm, knowledge, learnings and contributions with the CBOI/BioCytics mission and vision with patients as our North Star."

Please join us in welcoming him to the BioCytics and Carolina BioOncology Institute team! 💙

Biocytics, Inc., in partnership with Carolina BioOncology Institute, PLLC, is proud to announce the launch of an exciting research initiative in collaboration with UNC Charlotte!

Led by principal investigator Richard Allen White III, Ph.D., Associate Professor of Bioinformatics and Genomics at UNC Charlotte, and Renaud Warin, Ph.D., Chief Scientific Officer of BioCytics, the "Unlocking the Dark Genome of Cancer via Integrated Multi-Omics Platform of Discovery" initiative aims at identifying relevant genomic features that contribute to cancer cell growth and response to treatment.

Read more about it at https://shorturl.at/XQrkI